BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 16428034)

  • 1. Epidemiology and molecular biology of Barrett esophagus.
    Casson AG; Williams L; Guernsey DL
    Semin Thorac Cardiovasc Surg; 2005; 17(4):284-91. PubMed ID: 16428034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical and endoscopic factors predict higher pathologic grades of Barrett dysplasia.
    Anandasabapathy S; Jhamb J; Davila M; Wei C; Morris J; Bresalier R
    Cancer; 2007 Feb; 109(4):668-74. PubMed ID: 17211862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Polymorphism/loss of heterozygosity of APC gene in GERD-Barrett's metaplasia-dysplasia-adenocarcinoma sequence].
    Mokrowiecka A; Wierzchniewska-Ławska A; Smolarz B; Romanowicz-Makowska H; Malecka-Panas E
    Pol Merkur Lekarski; 2009 May; 26(155):385-9. PubMed ID: 19606680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarkers in the molecular pathogenesis of esophageal (Barrett) adenocarcinoma.
    Williams LJ; Guernsey DL; Casson AG
    Curr Oncol; 2006 Feb; 13(1):33-43. PubMed ID: 17576439
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The molecular biology of esophageal adenocarcinoma.
    Koppert LB; Wijnhoven BP; van Dekken H; Tilanus HW; Dinjens WN
    J Surg Oncol; 2005 Dec; 92(3):169-90. PubMed ID: 16299787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Barrett's esophagus: can biomarkers predict progression to malignancy?
    Tischoff I; Tannapfel A
    Expert Rev Gastroenterol Hepatol; 2008 Oct; 2(5):653-63. PubMed ID: 19072343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclin D1 polymorphism (G870A) and risk for esophageal adenocarcinoma.
    Casson AG; Zheng Z; Evans SC; Geldenhuys L; van Zanten SV; Veugelers PJ; Porter GA; Guernsey DL
    Cancer; 2005 Aug; 104(4):730-9. PubMed ID: 15971196
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study.
    Sikkema M; Kerkhof M; Steyerberg EW; Kusters JG; van Strien PM; Looman CW; van Dekken H; Siersema PD; Kuipers EJ
    Am J Gastroenterol; 2009 Nov; 104(11):2673-80. PubMed ID: 19638963
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of Barrett's esophagus with dysplasia.
    Hagen JA
    Semin Thorac Cardiovasc Surg; 1997 Jul; 9(3):285-9. PubMed ID: 9263347
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paget cells in the esophagus: assessment of their histopathologic features and near-universal association with underlying esophageal adenocarcinoma.
    Abraham SC; Wang H; Wang KK; Wu TT
    Am J Surg Pathol; 2008 Jul; 32(7):1068-74. PubMed ID: 18496141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dysplasia arising in barrett's esophagus: diagnostic pitfalls and natural history.
    Goldblum JR; Lauwers GY
    Semin Diagn Pathol; 2002 Feb; 19(1):12-9. PubMed ID: 11936261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastroesophageal reflux disease, Barrett esophagus, and esophageal adenocarcinoma.
    Chang JT; Katzka DA
    Arch Intern Med; 2004 Jul; 164(14):1482-8. PubMed ID: 15277277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnosis and recognition of early esophageal neoplasia.
    Herszényi L; Pregun I; Tulassay Z
    Dig Dis; 2009; 27(1):24-30. PubMed ID: 19439957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A clinical and histopathologic focus on Barrett esophagus and Barrett-related dysplasia.
    Voltaggio L; Montgomery EA; Lam-Himlin D
    Arch Pathol Lab Med; 2011 Oct; 135(10):1249-60. PubMed ID: 21970480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Barrett esophagus and Barrett carcinoma].
    Kruyt PH; van Sandick JW; van Lanschot JJ; Offerhaus GJ; Tytgat GN; Obertop H
    Ned Tijdschr Geneeskd; 1997 May; 141(18):869-73. PubMed ID: 9273450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors for esophageal cancer development.
    Falk GW
    Surg Oncol Clin N Am; 2009 Jul; 18(3):469-85. PubMed ID: 19500737
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Gastroesophageal reflux disease and malignancy].
    Richert Z; Robaszkiewicz M
    Rev Prat; 2008 Sep; 58(13):1414-5, 1417, 1419-20. PubMed ID: 18924321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus.
    Vaughan TL; Kristal AR; Blount PL; Levine DS; Galipeau PC; Prevo LJ; Sanchez CA; Rabinovitch PS; Reid BJ
    Cancer Epidemiol Biomarkers Prev; 2002 Aug; 11(8):745-52. PubMed ID: 12163328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.